This understanding has inspired a therapeutic strategy in which antisense oligonucleotides (AO) are designed to restore the open reading frame by excluding disruptive exons so as to permit translation of a truncated dystrophin protein6–9, thus converting DMD to a milder BMD phenotype4, 5. Here, DMD is linked to Duchenne muscular dystrophy.